Synthesis and structure - activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease

Journal of Medicinal Chemistry

Volumn 39, Issue 2, 1996, Pages 570-581

  Klein, Joseph T ^a   Davis, Larry ^a   Olsen, Gordon E ^a   Wong, George S ^a   Huger, Francis P ^a   Smith, Craig P ^a   Petko, Wayne W ^a   Cornfeldt, Michael ^a   Wilker, Jeffrey C ^a   Blitzer, R D ^a   Landau, E ^a   Haroutunian, V ^a   Martin, Lawrence L ^a   Effland, Richard C ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BESIPIRDINE; INDOLE DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CHOLINERGIC TRANSMISSION; DRUG SYNTHESIS; MOUSE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ALZHEIMER DISEASE; ANIMALS; BIOGENIC AMINES; BRAIN; INDOLES; MAGNETIC RESONANCE SPECTROSCOPY; PARASYMPATHOLYTICS; PYRIDINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0030042625     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9506433     Document Type: Article

References (57)

1. Klein, J. T.; Davis, L.; Olsen, G.; Cornfeldt, M.; Huger, F.; Smith, C.; Petko, W.; Wilker, J.; Blitzer, R.; Landau, E.; Haroutunian, V.; Effland, R. C. Synthesis and SAR of HP 749 and related analogs: Potential therapeutic agents for Alzheimer's disease. Presented in part at the 201st ACS National Meeting, Atlanta, GA, April 1991, paper MEDI 66.
2. Evans, D. A.; Funkenstein, H. H.; Albert, M. S.; Scherr, P. A.; Cook, N. R.; Chown, M. J.; Hebert, L. E.; Hennekens, C. H.; Taylor, J. O. Prevalence of Alzheimer's disease in a community of older persons. J. Am. Med. Assoc. 1989, 262, 2551-2556.
3. Davies, P. and Maloney, A. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976, 2, 1403.
4. Bartus, R. T.; Dean, R. L.; Beer, B.; Lippa, A. S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217, 408-417.
5. Bartus, R. T.; Dean, R. L.; Pontecorvo, M. J.; Flicker, C. The cholinergic hypothesis: A historical overview, current perspective and future direction. Ann. N. Y. Acad. Sci. 1985, 444, 332-333.
6. Shutske, G. M.; Pierrat, F. A.; Kapples, K. J.; Cornfeldt, M. L.; Szewczak, M. R.; Huger, F. P.; Bores, G. M.; Haroutunian, V.; Davis, K. L. 9-Amino-1,2,3,4-tetrahydroacridin-1-ols: Synthesis and evaluation as potential Alzheimer's disease therapeutics. J. Med. Chem. 1989, 32, 1805-1813.
7. Hamer, R. R. L.; Helsley, G. C.; Chiang, Y.; Kurys, B. E.; Cornfeldt, M. L.; Szewczak, M. R.; Huger, F. P.; Bores, G. M.; Glamkowski, E. J.; Freed, B. S. Novel 1,2,3,3a,8,8a-Hexahydro1,3a,8-trimethylpyrrolo[2,3-b]indoles: Synthesis and evaluation as potential therapeutics for Alzheimer's disease. Presented at the 201st ACS National Meeting, Atlanta, GA, April 1991, paper MEDI 74.
8. Davies, P.; Katzman, R.; Terry, R. D. Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementia. Nature 1980, 288, 279-280.
9. Beal, M. F.; Mazurek, M. F.; Traan, V. T.; Chattha, G.; Bird, E. D.; Martin, J. B. Reduced numbers of somatostatin receptors in the cerebral cortex in Alzheimer's disease. Science 1985, 229, 289-291.
10. Hyman, B. T.; Van Hoesen, G. W.; Damasio, A. R. Alzheimer's disease: glutamate depletion in the hippocampal perforant pathway zone. Ann. Neurol. 1987, 22, 37-40.
11. Lowe, S. L.; Bowen, D. M.; Francis, P. T.; Neary, D. Ante mortem cerebral amino acid concentrations indicate selective degeneration of glutamate-enriched neurons in Alzheimer's disease. Neuroscience 1990, 3, 571-577.
12. Palmer, A. M.; Gershon, S. Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic? FASEB J. 1990, 4, 2745-2752.
13. Adolfsson, R.; Gottfries, C. G.; Roos, B. E.; Winblad, B. Changes in the brain catecholamines in patients with dementia of the Alzheimer type. Br. J. Psychiatry 1979, 135, 216-223.
14. Tomlinson, B. E.; Irving, D.; Blessed, G. Cell loss in the locus coeruleus in senile dementia of the Alzheimer type. J. Neurol. Sci. 1981, 49, 419-428.
15. Cross, A. J.; Crow, T. J.; Perry, E. K.; Perry, R. H.; Blessed, G.; Tomlinson, B.E. Reduced dopamine-beta-hydroxylase activity in Alzheimer's disease. Br. Med. J. 1981, 282, 93-94.
16. Thesleff, S. Aminopyridines and synaptic transmission. Neuroscience 1980, 5, 1413-1419.
17. Davis, L.; Kapples, K. J.; Klein, J. T.; Olsen, G. E.; Cornfeldt, M. L.; Huger, F. P.; Smith, C. P.; Petko, W. W.; Wilker, J. C.; Effland, R. C. Synthesis and SAR of heteroaryl analogs of the 4-pyridinyl-1H-indol-1-amine HP 749: Potential agents for the treatment of Alzheimer's disease. Presented at the 201st ACS National Meeting, Atlanta, GA, April 1991, poster MEDI 104.
18. Olsen, G. E.; Davis, L.; Kapples, K. J.; Klein, J. T.; Cornfeldt, M. L.; Huger, F. P.; Smith, C. P.; Petko, W. W.; Wilker, J. C.; Haroutunian, V.; Effland, R. C. Synthesis and SAR of substituted pyrroloaminopyridines as potential agents for the treatment of Alzheimer's disease Presented at the 201st ACS National Meeting, Atlanta, GA, April 1991, poster MEDI 105.
19. Davis, L.; Olsen, G. E.; Klein, J. T.; Kapples, K. J.; Huger, F. P.; Smith, C. P.; Petko, W. W.; Cornfeldt, M.; Effland, R. C. Substituted (pyrroloamino)pyridines: Potential agents for the treatment of Alzheimer's disease. J. Med. Chem. 1996, 39, 582-587.
20. Somei, M.; Natsume, M. 1-Aminoindoles. Tetrahedron Lett. 1974, 5, 461-462.
21. Bruix, M.; Castellanos, M. L.; Martin, M. R.; deMendoza, J. Regioselective nucleophilic substitution in activated 1-aminopyrazolium cations: A facile synthesis of 5-substituted 1-methylpyrazoles. Tetrahedron Lett. 1985, 26, 5485-5488.
22. Koga, N.; Anselme, J. P. The preparation of 1,1-diarylhydrazines. J. Org. Chem. 1968, 33, 3963-3964.
23. Alger, B. M.; Bradbury, S.; Keating, M.; Rees, C. W.; Storr, R. C.; Williams, M. T. 1,2,3-Benzotriazines. J. Chem. Soc., Perkin Trans. 1 1975, 31-40.
24. Yamamura, H. I.; Snyder, S. H. Muscarinic cholinergic binding in rat brain. Proc. Natl. Acad. Sci. U.S.A. 1974, 71, 1725-1729.
25. Aronstam, R. S.; Abood, L. G.; Hoss, W. Influence of sulfhydryl reagents and heavy metals on the functional state of the muscarinic acetylcholine receptor in rat brain. Mol. Pharmacol. 1978, 14, 575-586.
26. 3H]QNB displacement by cholinergic agonists and antagonists. Biochem. Pharmacol. 1983, 32, 377-379.
27. Hershenson, F. M.; Moos, W. H. Drug development for senile cognitive decline. J. Med. Chem. 1986, 29, 1125-1130.
28. Bammer, G. Pharmacological investigations of neurotransmitter involvement in passive avoidance responding: A review and some new results. Neurosci. Biobehav. Rev. 1982, 6, 274.
29. 2 adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science 1985, 1273-1279.
30. 2 antagonist, facilitates memory retrieval in the rat. Behav. Neural Biol. 1989, 51, 401-411.
31. Rodbell, M. The role of hormone receptors and GTP-regulatory proteins in membrane transduction. Nature 1980, 284, 17-22.
32. Huger, F. P.; Smith, C. P.; Petko, W. W.; Conway, P. G.; Effland, R. C.; Klein, J. T. HP 749, A potential therapeutic agent for Alzheimer's Disease: (II) Neurochemieal profile. Soc. Neurosci. Abs. 1990, 16, 612.
33. 3H]norepinephrine release from rat cortical slices by N-(n-propyl)-N-(4-pyridinyl)-1H-indol-1-amine. Drug Dev. Res. 1994, 32, 13-18.
34. 3H]norepinephrine from rat cortical slices and synaptosomes. Neurochem. Res. 1994, 19, 1265-1270.
35. Aronstam, R. S.; Narayanan, T. K. Temperature effect on the detection of muscarinic receptor-G protein interactions in ligand binding assays. Biochem. Pharmacol. 1988, 37, 1045-1049.
36. Bhargava, V. K.; Salamy, A.; McKean, C. M. Effect of cholinergic drugs on the brainstem auditory evoked responses (far-field) in rats. Neuroscience 1978, 3, 821-826.
37. Cornfeldt, M.; Wirtz-Brugger, F.; Szewczak, M.; Blitzer, R.; Landau, E.; Haroutunian, V.; Effland, R.; Klein, J.; Smith, C. HP 749: A pharmacological profile of a therapeutic agent for Alzheimer's disease; I. Soc. Neurosci. Abs. 1990, 16, 612.
38. Santucci, A. C.; Haroutunian, V.; Davis, K. L. Pharmacological alleviation of combined cholinergic/noradrenergic lesion-induced memory deficits in rats. Clin. Neuropharm. 1991, 14 (Suppl. 1), S1-S8.
39. Huger, F. P.; Wirtz-Brugger, F.; Plummer, M. R.; Smith, C. P.; Rush, D. K.; Szewczak, M. R. Comparative neuropharmacology of besipirdine (HP 749) and 4-aminopyridine. Submitted for publication.
40. In clinical trials as the hydrochloride salt (besipirdine hydrochloride, HP 749).
41. Benesova, O.; Nahunek, K. Correlation between the experimental data from animal studies and therapeutic effects of antidepressant drugs. Psychopharmacologia 1971, 20, 337-347.
42. Ong, H. H.; Profitt, J. A.; Anderson, V. B.; Kruse, H.; Wilker, J. C.; Geyer, H. M., III. Novel tetracyclic spiropiperidines. 1. 3-Aryl-1,3-dihydrospiro[benzo[c]thiophene-1,4′-piperidines] as potential antidepressants. J. Med. Chem. 1981, 24, 74-79.
43. Rush, D. K. Scopolamine amnesia of passive avoidance: A deficit of information acquisition. Behav. Neural Biol. 1988, 50, 255-274.
44. Huger, F. P.; Smith, C. P.; Chiang, Y.; Glamkowski, E. J.; Ellis, D. B. Pharmacological evaluation of HP 370, a potential atypical antipsychotic agent: 2. In vitro profile. Drug Dev. Res. 1987, 11, 169-175.
45. Peroutka, S. J.; U'Prichard, D. C.; Greenberg, D. A.; Snyder, S. H. Neuroleptic drug interactions with norepinephrine α receptor binding sites in rat brain. Neuropharmacology 1977, 16, 549-556.
46. U'Prichard, D. C.; Greengerg, D. A.; Snyder, S. H. Binding characteristics of a radiolabeled agonist and antagonist at central nervous system α noradrenergic receptors. Mol. Pharmacol. 1977, 13, 454-473.
47. Starke, K.; Borowski, E.; Endo, T. Preferential blockade of presynaptic α-adrenoreceptors by yohimbine. Eur. J. Pharmacol. 1975, 34, 385-388.
48. 2-adrenoceptors in the rat brain cortex. Eur. J. Pharmacol. 1983, 95, 79-85.
49. Martin, L. L.; Lee, G. E.; Lee, T. B. K.; Rush, D. K.; Wilmot, C. A.; Paulus, E.; Elben, U.; Grome, J. J.; Porsche-Wiebking, E.; Rudolphi, K. A.; Stoll, P. Synthesis, resolution and SAR of (±)-2-amino-N-methyl-α-(3-methyl-2-thienyl)benzeneethanamine and related analogs as noncompetitive NMDA antagonists with neuroprotective properties. J. Med. Chem. 1994, 37, 3008-3015.
50. 3H]nitrendipine to receptors for calcium channel antagonists in the heart, cerebral cortex and ileum. Life Sci. 1982, 30, 2191-2202.
51. 1 recognition site. Eur. J. Pharmacol. 1983, 90, 151-153.
52. Mansour, A.; Lewis, M. E.; Khachaturian, H.; Akil, H.; Watson, S. J. Pharmacological and anatomical evidence of selective μ, δ, and κ opioid receptor binding in rat brain. Brain Res. 1986, 399, 69-79.
53. Kosterlitz, H. W.; Paterson, S. J.; Robson, L. E. Characterization of the κ-subtype of the opiate receptor in the guinea pig brain. Br. J. Pharmacol. 1981, 73, 939-949.
54. 2 receptor subtypes. Life Sci. 1983, 32, 3001-3011.
55. Huger, F. P.; Smith, C. P. Receptor binding assays for muscarinic cholinergic agonists. In Clinical Pharmacology: O'Brien, R. A., Ed.; Marcel Dekker: New York, 1986; Vol. 5, Receptor Binding in Drug Research.
56. 3H]methylcarbamylcholine binding sites in rat brain. J. Neurochem. 1989, 52, 483-491.
57. Ellman, G. L.; Courtney, K. D.; Andres, V.; Featherstone, R. M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7, 88-95.